NHMRC grants lure eminent immunologist home
12 November, 2004 by Melissa TrudingerExpatriate Australian immunologist Prof Jonathan Sprent will return to Australia next year from the Scripps Research Institute in San Diego, California, to take up a position at Sydney's Centenary Institute after being awarded a prestigious Burnet Award from the National Health and Medical Research Council (NHMRC).
Biotron publishes SARS research
11 November, 2004 by Melissa TrudingerCanberra biotech company Biotron (ASX:BIT) has published the results of its SARS virus ion channel research in the journal Virology.
Sydney team joins global paediatric cancer fight
05 November, 2004 by Melissa TrudingerSydney's Children's Cancer Institute Australia (CCIA) has joined leading paediatric cancer institutes in the US including St Jude Children's Research Hospital, Children's Hospital of Los Angeles, Children's Hospital of Philadelphia, Duke University Medical Centre, and Memorial Sloan- Kettering Cancer Centre to test new cancer drugs for the treatment of childhood cancers.
Novogen soars as subsidiary hits the fast track
05 November, 2004 by Renate KrelleInvestors added more than AUD$1 -- or 20 per cent -- to Novogen's (ASX:NRT) share price today on the news that the company's subsidiary Marshall Edwards (Nasdaq: MSHL/LSE AIM:MSH) had been granted fast-track status for the use of phenoxodiol in recurrent ovarian cancer.
Mouse model may provide link between metabolism, disease
04 November, 2004 by Graeme O'NeillA gene called c-Cbl ('see sybil') has emerged as a hot -- literally -- new lead into the genetic maze linking differences in energy metabolism to obesity and type 2 diabetes.
NZ's Neuren eyes Australian capital markets
01 November, 2004 by Melissa TrudingerNew Zealand biotechnology company Neuren Pharmaceuticals is evaluating possible options in Australia for raising capital, including private equity and an IPO on the ASX.
Prima secures $10m and institutional support
27 October, 2004 by Melissa TrudingerPrima Biomed (ASX: PRR) announced today it had finalised its $10 million placement to institutional and sophisticated investors.
Qld team hits new target in fat research
27 October, 2004 by Graeme O'NeillA research team at the University of Queensland has identified a promising new target for an anti-obesity therapy: an enzyme that appears to have a central role in the development of fat-storage cells called adipocytes.
Onyx falls behind in cancer drug race
26 October, 2004 by Staff WritersOnyx Pharmaceuticals - which is developing one of the most promising new cancer therapies on the horizon - has said it will not file for US approval of its kidney cancer drug as soon as some investors had anticipated.
Prima finalising $10m capital raising
25 October, 2004 by Melissa TrudingerPrima Biomed (ASX: PRR) has called a trading halt as it finalises a $10 million capital raising to institutional and sophisticated investors.
FDA approves wrinkle filler
19 October, 2004 by Staff WritersThe FDA has approved a new injectable gel, made by Genzyme and marketed by Inamed, that can be used to temporarily fill the deepest facial wrinkles.
In brief: Prana, ES Cell, Phosphagenics
14 October, 2004 by Melissa TrudingerAlzheimer's specialist Prana Biotechnology (ASX:PRR) has released data from an extension study of its Phase II PBT-1 (clioquinol) trial, showing that the drug appeared to slow the rate of decline.
Avexa forms new research partnerships
13 October, 2004 by Renate KrelleNear enough isn't good enough when it comes to structure-based drug design and medicinal chemistry. That's the reasoning behind Avexa's (ASX:AVX) new collaborations with Melbourne's St Vincent's Institute of Medical Research and the Shanghai Institute of Organic Chemistry, according to CEO Julian Chick.
AustCancer attracts $2m investment
08 October, 2004 by Melissa TrudingerUS biotech company Bioaccelerate will invest AUD$1.88 million into Australian Cancer Technologies (AustCancer, ASX:ACU) through a private share placement of 4,893,301 ACU shares at $0.384 per share.
Antisense to establish ADR program
07 October, 2004 by Melissa TrudingerAntisense Therapeutics (ASX: ANP) announced this week it would establish a level 1 American Depository Receipts (ADR) program in the US through the Bank of New York.
